Uptake of the anthracycline pirarubicin into mouse M5076 ovarian sarcoma cells via a sodium-dependent nucleoside transport system

Cancer Chemotherapy and Pharmacology

Volumn 55, Issue 3, 2005, Pages 222-230

  Nagai, Katsuhito ^a   Nagasawa, Kazuki ^a   Fujimoto, Sadaki ^a  

^a KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Anthracycline; Chemotherapy; De novo resistance; M5076 cell; Nucleoside transport system

Indexed keywords

ANTHRACYCLINE; FORMYCIN B; NUCLEOSIDE TRANSPORTER; PIRARUBICIN; ZIDOVUDINE;

ANIMAL CELL; ARTICLE; CELL TRANSPORT; CONTROLLED STUDY; DRUG UPTAKE; EFFUSION; FEMALE; GENETIC TRANSFECTION; MOUSE; NONHUMAN; NUCLEOSIDE TRANSPORT; OVARY TUMOR; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SARCOMA; TRANSPORT KINETICS;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; DOXORUBICIN; FEMALE; MICE; NUCLEOSIDE TRANSPORT PROTEINS; OVARIAN NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SODIUM; TRANSFECTION; TUMOR CELLS, CULTURED; URIDINE;

EID: 12444330293     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-004-0861-7     Document Type: Article

References (30)

1. Barcelo F, Barcelo I, Gavilanes F, Ferragut JA, Yanovich S, Gonzalez-Ros JM (1986) Interaction of anthracyclines with nucleotides and related compounds studied by spectroscopy. Biochim Biophys Acta 884:172-181
2. Barthelemy-Clavey V, Maurizot JC, Dimicoli JL, Sicard P (1974) Self-association of daunorubicin. FEBS Lett 46:5-10
3. Blum RH, Carter SK (1974) Adriamycin. A new anticancer drug with significant clinical activity. Ann Intern Med 80:249-259
4. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254
5. Cabral S, Leis S, Bover L, Nembrot M, Mordoh J (1984) Dipyridamole inhibits version by thymidine of methotrexate effect and increases drug uptake in Sarcoma 180 cells. Proc Natl Acad Sci U S A 81:3200-3203
6. Cass CE, Young JD, Baldwin SA (1998) Recent advances in the molecular biology of nucleoside transporters of mammalian cells. Biochem Cell Biol 76:761-770
7. Chan TC (1989) Augmentation of 1-beta-D-arabinofuranosylcytosine cytotoxicity in human tumor cells by inhibiting drug efflux. Cancer Res 49:2656-2660
8. Damaraju VL, Damaraju S, Young JD, Baldwin SA, Mackey J, Sawyer MB, Cass CE (2003) Nucleoside anticancer drugs: the role of nucleoside transporters in resistance to cancer chemotherapy. Oncogene 22:7524-7536
9. Doyle LA, Ross DD (2003) Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 22:7340-7358
10. Eksborg S (1978) Extraction of daunorubicin and doxorubicin and their hydroxyl metabolites: self-association in aqueous solution. J Pharm Sci 67:782-785
11. Gaffen JD, Chambers EA, Bennett A (1989) The effects of dipyridamole and indomethacin on methotrexate cytotoxicity in LoVo human colon cancer cells. J Pharm Pharmacol 41:350-352
12. Goh LB, Mack P, Lee CW (1995) Nitrobenzylthioinosine-binding protein overexpression in human breast, liver, stomach and colorectal tumor tissues. Anticancer Res 15:2575-2579
13. Griffith D, Jarvis SM (1996) Nucleoside and nucleobase transport systems of mammalian cells. Biochim Biophys Acta 1286:153-181
14. Hazlehurst LA, Landowski TH, Dalton WS (2003) Role of the tumor microenvironment in mediating de novo resistance to drugs and physiological mediators of cell death. Oncogene 22:7396-7402
15. Hyde RJ, Cass CE, Young JD, Baldwin SA (2001) The ENT family of eukaryote nucleoside and nucleobase transporters: recent advances in the investigation of structure/function relationships and the identification of novel isoforms. Mol Membr Biol 18:53-63
16. Krishna R, Mayer LD (2001) Modulation of P-glycoprotein (PGP) mediated multidrug resistance (MDR) using chemosensitizers: recent advances in the design of selective MDR modulators. Curr Med Chem Anti-Canc Agents 1:163-174
17. Mcclean S, Hill BT (1992) An overview of membrane, cytosolic and nuclear proteins associated with the expression of resistance to multiple drugs in vitro. Biochim Biophys Acta 1114:107-127
18. Micha P, Naz C, Irina S, Ying Z, Imogen RC (2001) Differential expression of human nucleoside transporters in normal and tumor tissue. Biochem Biophys Res Commun 280:951-959
19. Nagai K, Nagasawa K, Sadzuka Y, Tsujimoto M, Takara K, Ohnishi N, Yokoyama T, Fujimoto S (2002) Relationships between the in vitro cytotoxicity and transport characteristics of pirarubicin and doxorubicin in M5076 ovarian sarcoma, and comparison with those in Ehrlich ascites carcinoma cells. Cancer Chemother Pharmacol 49:244-250
20. Nagai K, Nagasawa K, Ishimoto A, Fujimoto S (2003) Pirarubicin is taken up by undine-transportable sodium-dependent concentrative nucleoside transporter in Ehrlich ascites carcinoma cells. Cancer Chemother Pharmacol 51:512-518
21. Nagasawa K, Natazuka T, Chihara K, Kitazawa F, Tsumura A, Takara K, Nomiyama M, Ohnishi N, Yokoyama T (1996) Transport mechanism of anthracycline derivatives in human leukemia cell lines: uptake and efflux of pirarubicin in HL60 and pirarubicin-resistant HL60 cells. Cancer Chemother Pharmacol 37:297-304
22. Nagasawa K, Ohnishi N, Yokoyama T (1998) Possibility of contribution of nucleoside transport systems to pirarubicin uptake by HL60 cells but not mononuclear cells. Jpn J Cancer Res 89:673-680
23. Nagasawa K, Nagai K, Ohnishi N, Yokoyama T, Fujimoto S (2001) Contribution of specific transport systems to anthracycline transport in tumor and normal cells. Curr Drug Metab 2:355-366
24. Nagasawa K, Nagai K, Ishimoto A, Fujimoto S (2003) Transport mechanism of lovastatin acid in bovine kidney NBL-1 cells: kinetic evidences imply involvement of monocarboxylate transporter 4. Int J Pharm 262:63-73
25. Patel S, Sprung AU, Keller BA, Heaton VJ, Fisher LM (1997) Identification of yeast DNA topoisomerase II mutants resistant to the antitumor drug doxorubicin: implications for the mechanisms of doxorubicin action and cytotoxicity. Mol Pharmacol 52:658-666
26. +-nucleoside cotransporter proteins (hCNT3 and mCNT3) broadly selective for purine and pyrimidine nucleosides (system cib). J Biol Chem 276:2914-2927
27. Shan K, Lincoff AM, Young JB (1996) Anthracycline-induced cardiotoxicity (see comments). Ann Intern Med 125:47-58
28. Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y (1982) 4′-O- Tetrahydropyranyladriamycin as a potential new antitumor agent. Cancer Res 42:1462-1467
29. Wijnholds J (2002) Drug resistance caused by multidrug resistance-associated proteins. Novartis Found Symp 243:69-79
30. Yao SY, Cass CE, Young JD (1996) Transport of the antiviral nucleoside analogs 3′-azido-3′-deoxythymidine and 2′,3′- dideoxycytidine by a recombinant nucleoside transporter (rCNT) expressed in Xenopus laevis oocytes. Mol Pharmacol 50:388-393